Tobias Breidthardt1, Cathrin Balmelli2, Raphael Twerenbold2, Tamina Mosimann2, Jaqueline Espinola3, Philip Haaf4, Gregor Thalmann2, Berit Moehring5, Mira Mueller2, Bernadette Meller2, Tobias Reichlin6, Karsten Murray2, Ronny Ziller2, Pascal Benkert7, Stefan Osswald4, Christian Mueller4. 1. Department of Nephrology, University Hospital Basel, Basel, Switzerland; Department of Internal Medicine, University Hospital Basel, Basel, Switzerland. Electronic address: breidthardtt@uhbs.ch. 2. Department of Internal Medicine, University Hospital Basel, Basel, Switzerland; Department of Cardiology, University Hospital Basel, Basel, Switzerland. 3. Department of Internal Medicine, University Hospital Zurich, Zurich, Switzerland. 4. Department of Cardiology, University Hospital Basel, Basel, Switzerland. 5. Department of Internal Medicine, University Hospital Basel, Basel, Switzerland. 6. Department of Cardiology, University Hospital Basel, Basel, Switzerland; Clinical Trial Unit, University Hospital Basel, Basel, Switzerland. 7. Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Abstract
BACKGROUND: Biomarkers may help to monitor and tailor treatment in patients with acute heart failure (AHF). METHODS AND RESULTS: Levels of ST2, a novel biomarker integrating hypervolemic cardiac strain and proinflammatory signals, were measured at presentation to the emergency department (ED) and after 48 hours in 207 patients with AHF. Patients were stratified according to their early ST2 response (responders: ST2 decrease ≥25%; nonresponders: ST2 decrease <25%) and beta-blocker, renin-angiotensin-aldosterone system (RAAS) blockade, or diuretic treatment status at hospital discharge. We assessed the utility of ST2 levels and its changes to predict long-term mortality and the interaction between ST2 levels, treatment at discharge, and 1-year mortality. ST2 levels were higher in nonsurvivors than in survivors (median 108 vs 69 ng/mL; P < .01) and decreased significantly during the 1st 48 hours (median decrease 33%). ST2 decrease was less in nonsurvivors compared with survivors (median -25% vs -42%; P < .01). In Cox regression, early ST2 changes independently predicted 1-year mortality (hazard ratio 1.07 for every increase of 10%; P = .02). RAAS blockers at discharge were associated with survival independently from ST2 response, whereas the association of beta-blockers with survival differed markedly according to ST2 response, with beneficial effects restricted to ST2 nonresponders (P interaction = .04). A similar, albeit nonsignificant, trend was observed for diuretics (P interaction = .11). CONCLUSIONS: ED and serial ST2 measurements are independent predictors of 1-year mortality in AHF.
BACKGROUND: Biomarkers may help to monitor and tailor treatment in patients with acute heart failure (AHF). METHODS AND RESULTS: Levels of ST2, a novel biomarker integrating hypervolemic cardiac strain and proinflammatory signals, were measured at presentation to the emergency department (ED) and after 48 hours in 207 patients with AHF. Patients were stratified according to their early ST2 response (responders: ST2 decrease ≥25%; nonresponders: ST2 decrease <25%) and beta-blocker, renin-angiotensin-aldosterone system (RAAS) blockade, or diuretic treatment status at hospital discharge. We assessed the utility of ST2 levels and its changes to predict long-term mortality and the interaction between ST2 levels, treatment at discharge, and 1-year mortality. ST2 levels were higher in nonsurvivors than in survivors (median 108 vs 69 ng/mL; P < .01) and decreased significantly during the 1st 48 hours (median decrease 33%). ST2 decrease was less in nonsurvivors compared with survivors (median -25% vs -42%; P < .01). In Cox regression, early ST2 changes independently predicted 1-year mortality (hazard ratio 1.07 for every increase of 10%; P = .02). RAAS blockers at discharge were associated with survival independently from ST2 response, whereas the association of beta-blockers with survival differed markedly according to ST2 response, with beneficial effects restricted to ST2 nonresponders (P interaction = .04). A similar, albeit nonsignificant, trend was observed for diuretics (P interaction = .11). CONCLUSIONS: ED and serial ST2 measurements are independent predictors of 1-year mortality in AHF.
Authors: Fernando Friões; Patrícia Lourenço; Olga Laszczynska; Pedro-Bernardo Almeida; João-Tiago Guimarães; James L Januzzi; Ana Azevedo; Paulo Bettencourt Journal: Clin Res Cardiol Date: 2015-01-14 Impact factor: 5.460
Authors: Lindsey Aurora; Edward Peterson; Hongsheng Gui; Nicole Zeld; James McCord; Yigal Pinto; Bernard Cook; Hani N Sabbah; L Keoki Williams; James Snider; David E Lanfear Journal: Clin Chim Acta Date: 2020-09-12 Impact factor: 3.786
Authors: Anna J Meredith; Darlene L Y Dai; Virginia Chen; Zsuzsanna Hollander; Raymond Ng; Annemarie Kaan; Scott Tebbutt; Krishnan Ramanathan; Anson Cheung; Bruce M McManus Journal: ESC Heart Fail Date: 2015-11-24
Authors: Cheyenne C S Tseng; Manon M H Huibers; Lonneke H Gaykema; Erica Siera-de Koning; Faiz Z Ramjankhan; Alan S Maisel; Nicolaas de Jonge Journal: Eur J Clin Invest Date: 2018-02-02 Impact factor: 4.686
Authors: Chris J Watson; Isaac Tea; Eoin O'Connell; Nadezhda Glezeva; Shuaiwei Zhou; Stephanie James; Joe Gallagher; James Snider; James L Januzzi; Mark T Ledwidge; Ken M McDonald Journal: J Cell Mol Med Date: 2020-04-29 Impact factor: 5.310